Vaccine Seen to Lessen Signs of Neurodegeneration in Phase 2 Trial

Vaccine Seen to Lessen Signs of Neurodegeneration in Phase 2 Trial

300259

Vaccine Seen to Lessen Signs of Neurodegeneration in Phase 2 Trial

AADvac1, an investigational vaccine targeting abnormal tau protein, a hallmark of Alzheimer’s disease, was found to be safe and effectively reduced the signs of neurodegeneration in patients with mild disease, according to data from the ADAMANT Phase 2 clinical trial. In a subgroup of participants with a confirmed Alzheimer’s biomarker profile, AADvac1 significantly slowed clinical and functional decline, the scientists noted. “The recent approval of an amyloid-based therapy [Aduhelm] was encouraging for the whole Alzheimer’s…

You must be logged in to read/download the full post.